MASH/NAFLD Microbiome-LBP Preclinical Efficacy Package

Creative Biolabs supports liver disease, metabolic disorder, and gut-liver axis teams building live biotherapeutic candidates for MASH/NAFLD. Our package combines diet-induced efficacy models, liver inflammation and fibrosis markers, bile acid/metabolomics profiling, and microbiome readouts to generate a practical preclinical proof-of-concept dataset with clear study-design logic for candidate selection and next-step planning.

Preclinical Efficacy Planning for Gut-Liver Axis LBP Programs

MASH/NAFLD microbiome programs often reach a difficult preclinical point: the candidate has functional promise, but the team still needs a model-driven efficacy package that connects liver phenotype, metabolic biology, gut community response, and mechanism-of-action evidence. Without this alignment, promising LBP concepts can remain difficult to compare, prioritize, or defend in partner discussions.

For liver disease, metabolic disorder, and gut-liver axis teams, fragmented endpoints can slow candidate selection and weaken partner-facing confidence. The goal is not simply to show a liver-marker change, but to explain whether the candidate is acting through a credible gut-liver axis mechanism. Creative Biolabs provides MASH/NAFLD Microbiome-LBP Preclinical Efficacy Package services that turn animal efficacy, metabolomics, and microbiome data into one coherent development story.

Core Package Outcomes

•Model and endpoint plan for MASH/NAFLD proof-of-concept
•Integrated liver, microbiome, and metabolite readout matrix
•Go/no-go evidence map for LBP candidate advancement

MASH/NAFLD Microbiome-LBP Preclinical Efficacy Service Scope

Creative Biolabs builds each package around the practical questions LBP teams must answer before advancing a MASH/NAFLD candidate: which model is appropriate, which endpoints matter, how the microbiome mechanism will be tested, and what evidence is needed for the next development decision.

What the Package Helps Your Team Establish

Preclinical proof-of-concept: whether the LBP candidate changes disease-relevant liver endpoints in a diet-induced MASH/NAFLD model.

Mechanistic plausibility: whether microbiome remodeling, bile acid patterns, metabolic signatures, or inflammatory pathways support the proposed gut-liver axis mechanism.

Development readiness: whether the current evidence is strong enough for lead selection, formulation refinement, follow-up efficacy studies, or partner-facing scientific discussion.

Core Technical Workstreams

Diet-Induced MASH/NAFLD Model Design

We help select model conditions, dosing schedules, sampling timepoints, comparator groups, and cohort logic suited to a microbiome-directed intervention rather than a conventional small-molecule study.

Live Biotherapeutic Dosing Feasibility

LBP dosing plans can incorporate viable count preparation, gavage schedule, anaerobe-sensitive handling, fecal recovery options, and strain or consortia tracking when applicable.

Liver Efficacy and Injury Endpoints

Study designs can include liver weight, serum ALT/AST, hepatic TG/TC, histology, NAFLD activity-style scoring, steatosis, lobular inflammation, ballooning, and tissue molecular markers.

Fibrosis and Inflammatory Biology

Fibrosis and inflammation modules may include Sirius Red, α-SMA, collagen-related markers, TLR pathway genes, TNF-α, IL-6, MCP-1, and tissue qPCR or immunostaining panels.

Bile Acid and Metabolomics Readouts

Targeted bile acid profiling, lipid mediator panels, amino acid signatures, SCFA-associated options, and pathway interpretation can be aligned to the candidate's proposed mechanism.

Microbiome Response Analysis

16S or metagenomic profiling, diversity metrics, differential taxa, functional inference, and candidate tracking can be integrated with liver and metabolite outcomes.

Preclinical Question	Creative Biolabs Support	Decision Value for LBP Teams
Does the candidate improve liver phenotype?	Diet-induced model execution with liver weight, serum chemistry, histology, steatosis, inflammation, and hepatic lipid readouts.	Supports lead confirmation and early proof-of-concept positioning.
Is the effect relevant to MASH progression biology?	Fibrosis, inflammatory cytokine, barrier-related, and pathway-marker modules tailored to the program hypothesis.	Clarifies whether the candidate affects more than simple steatosis.
Can mechanism be linked to the microbiome?	Microbiome sequencing, candidate tracking, bile acid/metabolomics, and integrated correlation-ready data organization.	Strengthens gut-liver axis mechanism framing for internal and external review.
What should happen after the study?	Gap assessment, follow-up endpoint recommendations, data-package summary, and next-study planning notes.	Helps teams prioritize development resources and avoid unfocused follow-up experiments.

Preclinical Efficacy Data Package Deliverables for MASH/NAFLD LBP Candidates

Each deliverable is structured for scientific review, candidate ranking, and follow-up study planning rather than a loose collection of assay outputs.

Study Design Blueprint

A model and endpoint plan covering group structure, dosing approach, sample map, primary readouts, secondary readouts, and optional mechanism panels.

Integrated Results Report

A report that organizes liver phenotype, histopathology, inflammatory markers, metabolomics, bile acid data, and microbiome results around the study question.

Gap and Next-Step Summary

A concise evidence map showing remaining data gaps, candidate risks, practical follow-up assays, and recommendations for the next preclinical stage.

Optional Add-On Readouts

Microbiome:
16S, metagenomics, candidate tracking, diversity and taxa shifts.

Metabolomics:
Bile acids, lipid mediators, amino acids, SCFA-associated options.

Tissue biology:
qPCR, IHC, barrier markers, inflammation and fibrosis panels.

Translation support:
Data-package framing for partner and internal development discussions.

Preclinical MASH/NAFLD LBP Study Workflow

A structured workflow keeps the animal model, LBP handling, endpoint selection, and integrated analysis aligned from project intake through final reporting.

Program Intake

Review strain or consortia format, available functional data, dosing constraints, target biology, and decision goals.

Model and Endpoint Lock

Define diet-induced model conditions, sampling schedule, liver endpoints, microbiome assays, and metabolite panels.

Execution and Sample Flow

Coordinate dosing, observation, necropsy, tissue processing, serum chemistry, histology, molecular assays, and fecal sampling.

Integrated Data Package

Deliver a decision-focused report linking phenotype, mechanism, unresolved gaps, and recommended next experiments.

Published Data Supporting MASH/NAFLD Microbiome-LBP Efficacy Readouts

Recent research evaluated human-derived Faecalibacterium prausnitzii strains in a high-fructose high-fat diet NASH mouse model using glucose homeostasis, serum chemistry, liver histology, fibrosis-associated endpoints, gut barrier markers, and liver inflammatory gene expression. The published data show why microbiome-LBP efficacy studies should measure both liver pathology and gut-liver axis biology.

The figure shows liver appearance, H&E-stained tissue, liver weight, and NAFLD activity scoring after bacterial intervention, illustrating the type of endpoint set needed for preclinical proof-of-concept. Creative Biolabs can provide related MASH/NAFLD LBP study support by integrating diet-induced models, liver phenotyping, metabolomics, and microbiome profiling.

F. prausnitzii effects on liver pathology and activity score. (OA Literature) — Fig.1 Effects of *Faecalibacterium prausnitzii* in preventing lipid accumulation in and damage to the liver. ^1,2

Why Creative Biolabs for MASH/NAFLD Microbiome-LBP Studies

Creative Biolabs supports early-stage LBP teams with study designs that respect both metabolic liver biology and live biotherapeutic development realities.

Disease-Model Fit

Model selection is matched to the team's proof-of-concept question, not applied as a generic liver-injury screen.

LBP-Aware Handling

Study planning can account for viability, anaerobic sensitivity, dosing preparation, and strain tracking needs.

Multi-Layer Readouts

Liver phenotype, microbiome, metabolomics, and inflammatory endpoints are planned as one connected package.

Decision-Ready Output

Reports are written to guide candidate advancement, follow-up study design, and evidence-gap closure.

Recommended Services for MASH/NAFLD LBP Programs

These existing Creative Biolabs services can be combined with the efficacy package when a program needs broader metabolic disease modeling, animal-study execution, or mechanism-of-action support.

Frequently Asked Questions

It is most useful after a candidate has preliminary identity, viability, and functional rationale, but before the team commits to larger efficacy studies, formulation decisions, or partner-facing claims.

Yes. The package can be scoped as a screening study across candidates or doses, then expanded into deeper liver pathology, metabolomics, and microbiome analysis for the strongest candidate.

Strong packages usually combine liver histology, serum injury markers, inflammatory or fibrosis markers, microbiome community data, and bile acid or metabolomics endpoints that match the proposed mechanism.

Yes. The report can identify efficacy, mechanism, stability, safety, and release-testing gaps that should be addressed before more advanced development packages are assembled.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video

References

Shin, Ji-Hee, et al. "Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet." Frontiers in Microbiology 14 (2023): 1123547. DOI
Distributed under Open Access license CC BY 4.0, without modification.

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

ISO 9001 Certified - Creative Biolabs Quality Management System.

Tel:
Fax:
Email:
Global

Inquiry Basket